US 12,350,192 B2
Ocular delivery systems and methods
David Y. Badawi, Glenview, IL (US); Daniel O'Keeffe, San Francisco, CA (US); and Paul Badawi, Atherton, CA (US)
Assigned to SIGHT SCIENCES, INC., Menlo Park, CA (US)
Filed by Sight Sciences, Inc., Menlo Park, CA (US)
Filed on Sep. 26, 2024, as Appl. No. 18/898,460.
Application 18/898,460 is a continuation of application No. 18/130,353, filed on Apr. 3, 2023, granted, now 12,127,973.
Application 18/130,353 is a continuation of application No. 17/827,494, filed on May 27, 2022, granted, now 11,617,679, issued on Apr. 4, 2023.
Application 17/827,494 is a continuation of application No. 17/553,671, filed on Dec. 16, 2021, granted, now 11,389,327, issued on Jul. 19, 2022.
Application 17/553,671 is a continuation of application No. 17/472,147, filed on Sep. 10, 2021, abandoned.
Application 17/472,147 is a continuation of application No. 17/239,263, filed on Apr. 23, 2021, granted, now 11,116,660, issued on Sep. 14, 2021.
Application 17/239,263 is a continuation of application No. 17/098,231, filed on Nov. 13, 2020, abandoned.
Application 17/098,231 is a continuation of application No. 16/189,882, filed on Nov. 13, 2018, granted, now 10,857,027, issued on Dec. 8, 2020.
Application 16/189,882 is a continuation of application No. 14/816,822, filed on Aug. 3, 2015, granted, now 10,179,066, issued on Jan. 15, 2019.
Application 14/816,822 is a continuation of application No. 13/644,748, filed on Oct. 4, 2012, granted, now 9,095,412, issued on Aug. 4, 2015.
Claims priority of provisional application 61/613,274, filed on Mar. 20, 2012.
Prior Publication US 2025/0009555 A1, Jan. 9, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61F 9/00 (2006.01); A61F 9/007 (2006.01)
CPC A61F 9/0008 (2013.01) [A61F 9/0017 (2013.01); A61F 9/007 (2013.01); A61F 9/00736 (2013.01); A61F 9/00781 (2013.01)] 30 Claims
OG exemplary drawing
 
1. A method for treating glaucoma comprising:
advancing a device at least partially through an anterior chamber of an eye and into Schlemm's canal, wherein the device comprises a conduit for delivering viscoelastic fluid to Schlemm's canal;
advancing the conduit along an arc of Schlemm's canal;
delivering about 50 μl of viscoelastic fluid to Schlemm's canal; and
after delivering the about 50 μl of viscoelastic fluid, disrupting trabecular meshwork to improve flow through a trabeculocanalicular outflow pathway.